Faculty Disclosures and Resolution of Conflict of Interest

Disclosure Policy
Baptist Health has a process in place to ensure balance, independence, objectivity and scientific rigor in CME programming. Through this process Baptist Health identifies and, when applicable, resolves conflicts of interest of all individuals in a position to control or influence CME content, including faculty, conference directors, planners, content reviewers, CME Committee members and the CME Department staff. The CME Department is responsible for content review and, when necessary, makes modifications to resolve conflicts of interest so final presentations are fair and unbiased. These efforts are intended to affirm that the educational content is not controlled or influenced – directly or indirectly – by a commercial interest. As defined by ACCME, a commercial interest is any entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.

Unapproved or Off-Label Use
Individuals participating in this CME activity are responsible for identifying references to off-label or unapproved product usage in their discussions and recommendations.

Non-faculty Contributors and other individuals involved in the planning, development, review and editing of the symposium content have indicated neither they nor their spouses/partners have relevant financial relationships.

Copyright
Baptist Health is not responsible for any image/illustration content prepared by faculty members for their presentations.

Disclosures
The following faculty members disclosed relevant financial relationships with commercial interest companies and their presentations will not include off-label or unapproved usage.

William Virgil Brown, M.D., has disclosed that he serves as a consultant to Amgen, Akcea, Esperion, Ionis, Kowa Pharma, Merck and Sanofi/Genzyme, and that he is a member of the Merck speaker’s bureau. Dr. Brown has indicated that his presentations will not include discussion of off-label or unapproved usage.

William Cushman, M.D., has disclosed that he receives grant/research support from Boehringer Ingelheim Pharmaceuticals and Eli Lilly, and that he serves as a consultant to Takeda Pharmaceuticals. Dr. Cushman has indicated that his presentations will not include discussion of off-label or unapproved usage.
Faculty Disclosures and Resolution of Conflict of Interest

Thomas Dayspring, M.D., has disclosed that he is an employee of True Health Diagnostics and a member of the Sanofi/Regeneron speaker’s bureau. Dr. Dayspring has indicated that his presentations will include discussion of off-label or unapproved usage.

Ian Del Conde Pozzi, M.D., has disclosed that he is a member of the speaker’s bureau for Bristol-Myers Squibb, Pfizer Pharmaceuticals and Janssen. Dr. Del Conde has indicated that his presentations will not include discussion of off-label or unapproved usage.

Sergio Fazio, M.D., Ph.D., has disclosed that he serves as a consultant to Amgen, Sanofi, Kowa Pharma and Aegerion Pharmaceuticals. Dr. Fazio has indicated that his presentations will not include discussion of off-label or unapproved usage.

Theodore Feldman, M.D., has disclosed that he is a member of the speaker’s bureau for Amgen, Regeneron, Sanofi, Novartis Pharmaceuticals and Merck. Dr. Feldman has indicated that his presentation will not include discussion of off-label or unapproved usage.

Adam Geronemus, M.D., has disclosed that he serves as a consultant to Merit Medical. Dr. Geronemus has indicated that his presentation will not include discussion of off-label or unapproved usage.

Anthony Gonzalez, M.D., has disclosed that he receives grant/research support from Intuitive Surgical and serves as a consultant to Ethicon, Intuitive Surgical and Minimally Invasive Devices; also, Dr. Gonzalez is a member of the speaker’s bureau for Mallinckrodt. Dr. Gonzalez has indicated that his presentation will not include discussion of off-label or unapproved usage.

Efrain Gonzalez, M.D., has disclosed that he receives grant/research support from AstraZeneca Pharmaceuticals, Bristol-Myers Squibb and Medtronic. Dr. Gonzalez has indicated that his presentation will not include discussion of off-label or unapproved usage.

Timothy Grant, M.D., has disclosed that he is a member of the Merck speaker’s bureau. Dr. Grant has indicated that his presentation will not include discussion of off-label or unapproved usage.

Carl Lavie, M.D., has disclosed that he serves as a consultant to and is a member of the speaker’s bureau for Bristol-Myers Squibb, Pfizer Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Amgen, Sanofi, Regeneron, Amarin Pharma, Upsher Smith, Kowa Pharma and DSM. Dr. Lavie has indicated that his presentations will not include discussion of off-label or unapproved usage.
Faculty Disclosures and Resolution of Conflict of Interest

Peter Libby, M.D., has disclosed that he serves as a consultant (including clinical trials) to Amgen, AstraZeneca Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and Company, Esperion, Genzyme, GlaxoSmithKline, Ionis Pharmaceuticals, Kowa Pharma, Merck & Co., Inc., Novartis Pharmaceuticals, Pfizer Pharmaceuticals, Sanofi/Regeneron and Takeda Pharmaceuticals; also, he is a member of the scientific advisory board for Athera Biotechnologies, DalCor Pharmaceuticals, Interleukin Genetics, Kowa Pharma and Novartis Pharmaceuticals. Dr. Libby receives grant/research support from General Electric, GlaxoSmithKline and Novartis Pharmaceuticals. Dr. Libby has indicated that his presentations will not include discussion of off-label or unapproved usage.

Ramon Lloret, M.D., has disclosed that he serves as a consultant to AstraZeneca Pharmaceuticals and Novartis Pharmaceuticals, and that he is a member of the speaker’s bureau for Amgen, AstraZeneca Pharmaceuticals and Novartis Pharmaceuticals. Dr. Lloret has indicated that his presentation will not include discussion of off-label or unapproved usage.

Michael Ozner, M.D., has disclosed that he is a member of the scientific advisory board for Life Extension and Nordic Naturals, and that he is a member of the speaker’s bureau for True Health Diagnostics. Dr. Ozner has indicated that his presentations will not include discussion of off-label or unapproved usage.

Ramon Quesada, M.D., has disclosed that he serves as a consultant to Abbott and Boston Scientific, and that he is a member of the speaker’s bureau for Abbott, Boston Scientific, St. Jude Medical, Volcano and Edwards Lifesciences. Dr. Quesada has indicated that his presentation will not include discussion of off-label or unapproved usage.

Peter Toth, M.D., Ph.D., has disclosed that he receives grant/research support from AstraZeneca Pharmaceuticals and serves as a consultant to Amarin Pharma, Amgen, AstraZeneca Pharmaceuticals, Kowa Pharma, Merck and Sanofi/Regeneron; also, Dr. Toth is a member of the speaker’s bureau for Amarin Pharma, Amgen, Kowa Pharma, Merck and Sanofi/Regeneron. Dr. Toth has indicated that his presentations will not include discussion of off-label or unapproved usage.

James Underberg, M.D., has disclosed that he receives grant/research support from Aegerion Pharmaceuticals and Pfizer Pharmaceuticals, and that he serves as a consultant to Amgen, Aegerion Pharmaceuticals, Alexion, Akcea, Amarin Pharma, Eli Lilly, Invitae, Kasfe, Merck, Recombine, Regeneron and Sanofi; also, Dr. Underberg is a member of the speaker’s bureau for Amgen, Alexion, Merck, Regeneron and True Health Diagnostics. Dr. Underberg has indicated that his presentations will not include discussion of off-label or unapproved usage.
Faculty Disclosures and Resolution of Conflict of Interest

Karol Watson, M.D., Ph.D., has disclosed that she serves as a consultant to Lilly and Merck. Dr. Watson has indicated that her presentations will not include discussion of off-label or unapproved usage.

Paul Ziajka, M.D., Ph.D., has disclosed that he receives grant/research support from Amgen, Regeneron and Sanofi, and that he is a member of the speaker's bureau for Amgen, Amarin Pharma, Kowa Pharma, Regeneron and Sanofi. Dr. Ziajka has indicated that his presentations will not include discussion of off-label or unapproved usage.

Nothing to Disclose
The following faculty members indicated that neither they nor their spouses/partners have relevant financial relationships with commercial interest companies, and they will not include off-label or unapproved product usage in their presentations or discussions: Arthur Agatston, Julio Barcena, M.D., Roger Blumenthal, M.D., Natalie Castro-Romero, R.D., Felipe De Los Rios La Rosa, M.D. and Khurram Nasir, M.D.